Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178501 | 1.00 | ALDH1A1 (0.56) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| Methylene Chloride SCHEMBL27458429 | 0.91 | ALDH1A1 (0.48) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| SCHEMBL16420054 | 0.84 | ALDH1A1 (0.47) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| SCHEMBL16574044 | 0.81 | CCNB2 (0.50) | ALDH1A1KDM4ECYP1A2NPC1RAB9A | |
| SCHEMBL31184279 | 0.78 | ALDH1A1 (0.45) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| SCHEMBL28542122 | 0.77 | RAB9A (0.46) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| SCHEMBL21467066 | 0.75 | ALDH1A1 (0.46) | ALDH1A1NQO2KDM4ECYP1A2NPC1 | |
| SCHEMBL21241352 | 0.74 | CCR1 (0.52) | ALDH1A1KDM4ECYP1A2NPC1RAB9A | |
| SCHEMBL5539375 | 0.73 | HTR1A (0.54) | ALDH1A1KDM4ECYP1A2NPC1RAB9A | |
| SCHEMBL5543680 | 0.73 | HTR1A (0.54) | ALDH1A1NQO2KDM4ECYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4151218-A1 | LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS | Boehringer Ingelheim International GmbH (DE) | 2023-03-22 | — | — | EP | claimed |
| CN-114805225-B | Hydrogenation method of methyl quinoxaline | 苏州中车氢能动力技术有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114805225-A | Hydrogenation method of methyl quinoxaline | 苏州中车氢能动力技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-113817173-B | Variable-rigidity self-repairing material containing metal-mercapto coordination bond and preparation and application thereof | 南京大学 | 2022-07-12 | — | — | CN | claimed |
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-06-16 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-113817173-A | Variable-rigidity self-repairing material containing metal-mercapto coordination bond and preparation and application thereof | 南京大学 | 2021-12-21 | — | — | CN | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-07-16 | — | — | US | claimed |
| EP-1756093-A1 | PROCESSES FOR PREPARING GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2006009736-A1 | PROCESSES FOR PREPARING GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | claimed |
| US-20050282820-A1 | Processes for preparing gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2005-12-22 | — | — | US | claimed |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-25 | — | — | US | claimed |
| US-6573379-B2 | Contacting 6-methyl quinoxaline with N- bromosuccinimide in the presence of a radical initiator in 1, 2-dichloroethane to form 6-bromomethyl quinoxaline | AIR PRODUCTS AND CHEMICALS, INC. | 2003-06-03 | — | — | US | claimed |
| US-6559308-B1 | The present invention relates to a method for preparing quinoxaline-5- and 6-carboxylic acids. The method comprises contacting an aqueous suspension of a 5- or 6-hydroxymethyl quinoxaline with oxygen in the presence of a transition metal | AIR PRODUCTS AND CHEMICALS, INC. | 2003-05-06 | — | — | US | claimed |
| US-20030050475-A1 | Method for preparing halomethyl heterocyclic compounds | BURDENIUC JUAN JESUS (US) | 2003-03-13 | — | — | US | claimed |
| EP-1283202-A1 | Method for preparing heterocyclic-carboxylic acids | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2003-02-12 | — | — | EP | claimed |
| EP-1277742-A1 | Method for preparing halomethyl heterocyclic compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2003-01-22 | — | — | EP | claimed |
| EP-0657499-B1 | Vulcanizable epichlorohydrin polymer composition | DAISO CO LTD (JP) | 1998-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184088-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 648/4885NQO2 1726/4885KDM4E 2319/4885 |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | ALDH1A1 412/4885NQO2 1162/4885KDM4E 895/4885 |
| US-20050282820-A1 | Processes for preparing gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | ALDH1A1 4797/4885NQO2 3229/4885KDM4E 1677/4885 |
| US-20030050475-A1 | Method for preparing halomethyl heterocyclic compounds | HDHD5, HNMT, CBR3 | ALDH1A1 2209/4885NQO2 7/4885KDM4E 594/4885 |
| US-20200222411-A1 | USES OF DPP IV INHIBITORS | DPP4, DPP3, DPP7 | ALDH1A1 648/4885NQO2 1726/4885KDM4E 2319/4885 |
| US-20050187227-A1 | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | ALDH1A1 249/4885NQO2 821/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.